39860-99-6 Usage
Description
Pipotiazine, a phenothiazine derivative, is an antipsychotic medication primarily used to treat various psychiatric disorders. It functions as a dopamine antagonist, exerting its effects through the modulation of dopamine receptors in the brain. This property makes it a valuable compound in the pharmaceutical industry for the treatment of schizophrenia and other related conditions.
Uses
Used in Pharmaceutical Industry:
Pipotiazine is used as an antipsychotic agent for the treatment of psychiatric disorders such as schizophrenia, schizoaffective disorder, and other psychotic conditions. Its ability to block dopamine receptors helps alleviate symptoms like hallucinations, delusions, and disorganized thinking associated with these disorders.
Used in Covid-19 Drug Repurposing:
Pipotiazine is being explored for its potential as a drug repurposed for Covid-19 treatment. Through virtual screening and consensus scoring, it has been identified as a potential small-molecule inhibitor of the spike protein-ACE2 receptor interaction, which is crucial for the virus's entry into human cells. This application aims to provide a new therapeutic approach to combat the SARS-CoV-2 virus and its associated complications.
Originator
Piportil, Rhone-Poulenc Rorer
Manufacturing Process
10-(3-Tetrahydropyranyloxypropyl)phenthiazine-2-sulfonic acid dimethylamide prepared by condensing 1-chloro-3-tetrahydropyranyloxy propane with phenthiazine-2-sulfonic acid dimethylamide (melting point 140°C) in xylene in the presence of sodamide.10-(3-Hydroxypropyl)phenthiazine-2-sulfonic acid dimethylamide was prepared by the action of hydrochloric acid in ethanol on 10-(3tetrahydropyranyloxypropyl)phenthiazine-2-sulfonic acid dimethylamide.10-(3-Methanesulphonyloxypropyl)phenthiazine-2-sulphonic acid dimethylamide, was obtained by condensing methanesulphonyl chloride in anhydrous pyridine with 10-(3-hydroxypropyl)phenthiazine-2-sulfonic acid dimethylamide.10-(3-Methanesulphonyloxypropyl)phenthiazine-2-sulfonic acid dimethylamide and 4-hydroxyethyl piperidine in toluene were heated under reflux with stirring. The reaction mixture was allowed to cool and water was added. The resulting toluene solution layer was decanted and washed twice with water. The toluene solution was then stirred with 5% hydrochloric acid. The hydrochloride of the desired phenthiazine base precipitated in gummy condition in the aqueous layer. This was decanted and treated with sodium hydroxide. It was then extracted three times with ethyl acetate. The extracts were dried over sodium sulfate, filtered and concentrated in vacuum. A resinous product was obtained. This product was dissolved in a mixture of benzene and cyclohexane and chromatographed on a column containing alumina. The chromatographed product was eluted successively with mixtures of benzene and cyclohexane and then with benzene and finally with a mixture of benzene and ethyl acetate. The eluates were evaporated to yield a crude product. This product was recrystallised from aqueous ethanol and yielded 10[3-[4-(2-hydroxyethyl)piperidyl]propyl]phenthiazine-2-sulfonic acid dimethylamide.
Therapeutic Function
Neuroleptic
Check Digit Verification of cas no
The CAS Registry Mumber 39860-99-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,9,8,6 and 0 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 39860-99:
(7*3)+(6*9)+(5*8)+(4*6)+(3*0)+(2*9)+(1*9)=166
166 % 10 = 6
So 39860-99-6 is a valid CAS Registry Number.
InChI:InChI=1/C24H33N3O3S2/c1-25(2)32(29,30)20-8-9-24-22(18-20)27(21-6-3-4-7-23(21)31-24)14-5-13-26-15-10-19(11-16-26)12-17-28/h3-4,6-9,18-19,28H,5,10-17H2,1-2H3
